LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

Search

Twist Bioscience Corp

Закрыт

СекторЗдравоохранение

49.12 3.76

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

48.52

Макс.

49.12

Ключевые показатели

By Trading Economics

Доход

-3.4M

-31M

Продажи

4.7M

104M

Рентабельность продаж

-29.419

Сотрудники

979

EBITDA

-3.2M

-24M

Рекомендации

By TipRanks

Рекомендации

Активная покупка

Прогноз на 12 месяцев

+5.88% upside

Дивиденды

By Dow Jones

Следующий отчет о доходах

4 мая 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

309M

2.9B

Предыдущая цена открытия

45.36

Предыдущая цена закрытия

49.12

Новостные настроения

By Acuity

50%

50%

127 / 351 Рейтинг в Healthcare

Техническая оценка

By Trading Central

Уверенность

Very Strong Bearish Evidence

Twist Bioscience Corp График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

15 февр. 2026 г., 23:21 UTC

Приобретения, слияния, поглощения

Qube Agrees to Takeover by MAM-Led Consortium Valuing Its Equity at $6.51 Billion

15 февр. 2026 г., 23:45 UTC

Обсуждения рынка

Nikkei May Rise as Fears About AI Disruption Recede -- Market Talk

15 февр. 2026 г., 23:40 UTC

Обсуждения рынка

Gold Falls on Possible Position Adjustments -- Market Talk

15 февр. 2026 г., 23:06 UTC

Отчет

Thai Beverage: Spirits, Beer Businesses Posted Satisfactory EBITDA Growth, Alongside Profit Margin Expansion>Y92.SG

15 февр. 2026 г., 23:04 UTC

Отчет

Thai Beverage 1Q Beer Business EBITDA THB4.64B, Up 4.7% on Year>Y92.SG

15 февр. 2026 г., 23:04 UTC

Отчет

Thai Beverage 1Q Spirits Business EBITDA THB8.50B, Up 6.9% on Year >Y92.SG

15 февр. 2026 г., 23:01 UTC

Отчет

Thai Beverage 1Q EBITDA THB16.75B, Up 1.8% on Year >Y92.SG

15 февр. 2026 г., 23:01 UTC

Отчет

Thai Beverage 1Q FY Sales Revenue THB86.70B, Down 6.0% on Year>Y92.SG

15 февр. 2026 г., 22:53 UTC

Приобретения, слияния, поглощения

Qube: MAM-Led Offer Implies A$11.7 Billion Enterprise Value

15 февр. 2026 г., 22:53 UTC

Приобретения, слияния, поглощения

Qube: UniSuper to Transfer 15.07% Stake to Equivalent Ownership of Consortium Holding Structure

15 февр. 2026 г., 22:52 UTC

Приобретения, слияния, поглощения

Qube Shareholders to Receive A$5.20/Share in Cash

15 февр. 2026 г., 22:52 UTC

Приобретения, слияния, поглощения

Qube Holdings Agrees to Takeover by Macquarie Asset Management-Led Consortium

15 февр. 2026 г., 22:22 UTC

Приобретения, слияния, поглощения

BlueScope CEO Tania Archibald Speaking on a Call With Media

15 февр. 2026 г., 22:17 UTC

Приобретения, слияния, поглощения

BlueScope CEO: Stresses Whyalla Project Would Have to Make Sense to Shareholders

15 февр. 2026 г., 22:16 UTC

Приобретения, слияния, поглощения

BlueScope CEO: Some Job Cuts Inevitable to Ensure Company is Competitive

15 февр. 2026 г., 22:14 UTC

Приобретения, слияния, поглощения

BlueScope CEO: Higher Returns Tied to End of Capital Investment Program

15 февр. 2026 г., 22:14 UTC

Приобретения, слияния, поглощения

BlueScope Steel CEO: Higher Returns After Rebuffed Takeover Bid a 'Natural Coincidence'

15 февр. 2026 г., 20:48 UTC

Отчет

BlueScope: Will Now Target Net Debt of Up to A$1.5 Billion; Will Surpass as Needed

15 февр. 2026 г., 20:47 UTC

Отчет

BlueScope: Expects Full Benefits of Further A$150M Cost Savings in FY 2027

15 февр. 2026 г., 20:46 UTC

Отчет

BlueScope: Recorded Net Annualized Cost Improvements of A$190 Million in 1H

15 февр. 2026 г., 20:45 UTC

Отчет

BlueScope Expects a One-Third Lower 2H Result From Asia Business Vs 1H

15 февр. 2026 г., 20:44 UTC

Отчет

BlueScope Expects 15% Higher 2H Result From North America Business Vs 1H

15 февр. 2026 г., 20:44 UTC

Отчет

BlueScope Expects Lower 2H Result From Australia Business Vs 1H

15 февр. 2026 г., 20:43 UTC

Отчет

BlueScope Expects 2H Underlying Ebit of A$620 Million-A$700 Million

15 февр. 2026 г., 20:42 UTC

Отчет

BlueScope Net Debt A$2.2 Million at Dec. 31

15 февр. 2026 г., 20:42 UTC

Отчет

BlueScope 1H Underlying Ebit A$557.5 Million, Up 81% On-Year

15 февр. 2026 г., 20:41 UTC

Отчет

BlueScope 1H Underlying Ebitda A$915.3 Million, Up 39% On-Year

15 февр. 2026 г., 20:40 UTC

Отчет

BlueScope 1H Underlying Profit A$382.0 Million Vs A$176.4 Million Year Prior

15 февр. 2026 г., 20:40 UTC

Отчет

BlueScope 1H Sales Revenue From Continuing Ops A$8.22 Billion, Up 4% On-Year

15 февр. 2026 г., 20:39 UTC

Отчет

BlueScope Intends to Spend A$310 Million on Buyback, Or Other Returns if Share Repurchases Limited

Сравнение c конкурентами

Изменение цены

Twist Bioscience Corp Прогноз

Целевая цена

By TipRanks

5.88% рост

Прогноз на 12 месяцев

Средняя 52 USD  5.88%

Максимум 58 USD

Минимум 50 USD

Основано на мнении 6 аналитиков Wall Street, спрогнозировавших целевые цены для Twist Bioscience Corp на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

6 ratings

6

Покупка

0

Удержание

0

Продажа

Техническая оценка

By Trading Central

31.56 / 38.6884Поддержка и Сопротивление

Краткосрочная

Very Strong Bearish Evidence

Среднесрочная

Bearish Evidence

Долгосрочная

Bearish Evidence

Настроения

By Acuity

127 / 351Рейтинг в Здравоохранение

Новостные настроения

Neutral

Волатильность

Ниже среднего

Объем новостей (RCV)

Средняя

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Twist Bioscience Corp

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
help-icon Live chat